Date | Price Target | Rating | Analyst |
---|---|---|---|
8/2/2024 | $26.00 → $39.00 | Underweight → Equal Weight | Barclays |
1/3/2024 | $33.00 | Underweight | Barclays |
11/3/2023 | $39.00 → $28.00 | Underweight → Equal Weight | Wells Fargo |
11/3/2023 | Buy → Neutral | BTIG Research | |
11/3/2023 | $70.00 → $39.00 | Neutral → Overweight | Piper Sandler |
10/11/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
9/26/2023 | $56.00 → $39.00 | Underweight | Wells Fargo |
8/2/2023 | $66.00 → $70.00 | Overweight → Neutral | Piper Sandler |
Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously
Barclays initiated coverage of Omnicell with a rating of Underweight and set a new price target of $33.00
Wells Fargo upgraded Omnicell from Underweight to Equal Weight and set a new price target of $28.00 from $39.00 previously
Full-Service, Scalable Solution Designed to Help Health Systems Establish and Continuously Optimize Centralized Medication Management Operations Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, today announced Central Med Automation Service, a subscription-based solution designed to help health systems establish and continuously optimize centralized medication management for Consolidated Pharmacy Services Centers (CPSCs) and similar operations. Central Med Automation Service is intended to streamline medication dispensing from a central fulfillment area throughout the entire health system enterprise, which is expected to enhance inventory visibility
Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 1:30 p.m. ET. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, software, and expert services, Omnicell solutions are helping healt
Good Neighbor Pharmacy Launches EnlivenHealth's New Scope of Practice and Reimbursement Snapshot at ThoughtSpot Designed to Drive Clinical Service Expansion, Reimbursement and Patient Care in Community Pharmacy EnlivenHealth, a division of Omnicell, Inc., is pleased to announce the release of a first-of-a-kind Scope of Practice and Reimbursement Snapshot solution for members of Good Neighbor Pharmacy, a national franchise for independent pharmacies offered through Cencora. This new resource is designed to empower Good Neighbor Pharmacy members by providing critical information on clinical services and reimbursement information tailored to each state. EnlivenHealth's Scope of Practice an
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
10-Q - OMNICELL, INC. (0000926326) (Filer)
8-K - OMNICELL, INC. (0000926326) (Filer)
S-8 - OMNICELL, INC. (0000926326) (Filer)
4 - OMNICELL, INC. (0000926326) (Issuer)
4 - OMNICELL, INC. (0000926326) (Issuer)
4 - OMNICELL, INC. (0000926326) (Issuer)
Benchmark analyst Bill Sutherland reiterates Omnicell (NASDAQ:OMCL) with a Buy and maintains $38 price target.
Benchmark analyst Bill Sutherland reiterates Omnicell (NASDAQ:OMCL) with a Buy and maintains $38 price target.
The table below summarizes Omnicell's second quarter and full year 2024 guidance outlined above. Q2 2024 2024 Bookings Not provided $750 million - $875 million Total Revenues $250 million - $260 million $1.045 billion - $1.120 billion Product Revenues $140 million - $145 million $605 million - $650 million Service Revenues $110 million - $115 million $440 million - $470 million Technical Services Revenues Not
FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me
Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e
Established Leader Brings Global SaaS and Healthcare Technology Experience to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced it has increased its number of board seats from 9 to 10, and has appointed Kaushik "Bobby" Ghoshal to fill the newest seat as an independent director of Omnicell's Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711576271/en/Omnicell Appoints Bobby Ghoshal to Board of Directors (Photo: Business Wire) Mr. Ghoshal is an established technology leader who brings more than
Results exceed previously issued second quarter guidance across all metrics Total revenues of $277 million GAAP net income per diluted share of $0.08 Non-GAAP net income per diluted share of $0.51 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its second quarter ended June 30, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased with the second quarter results that we announced today, which exceeded our previously issue
Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the second quarter 2024, before market open on Thursday, August 1, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3278878. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About Omnice
Results exceed prior first quarter guidance across all metrics Total GAAP revenues of $246 million Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its first quarter ended March 31, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased with the first quarter results that we announced today, which exceeded our previously issued guidance across all key metrics, including revenue, non-GAAP EBITDA and non-GAAP earnings per share." "As we have navigated through a challenging customer environment, we